Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2005
05/12/2005US20050100918 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100917 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100907 Method and medicament for inhibiting the expression of a given gene
05/12/2005US20050100901 Vaccine for treating nicotine addiction
05/12/2005US20050100621 comprising urea as an active ingredient, a vegetable oil or vegetable oil derivative, water, and conventional excipients
05/12/2005US20050100607 administering polyethylene glycol or ethylene oxide-propylene oxide copolymers, with drugs, to improve delivery in the alimentary canal
05/12/2005US20050100598 Quick disintegrating tablet in buccal cavity and production process thereof
05/12/2005US20050100597 salt of diclofenac with tromethamine; gingivitis, glossitis, stomatitis, aphthae, paradentosis, paradentitis, laryngitis, pharyngitis, mucositis of the oral cavity caused by radiotherapy and chemotherapy
05/12/2005US20050100593 Of gelatin and polyglutamic acid; inhibits an insolubilization phenomenon in the film that occurs during storage of the gelatin capsule; improves bioavailability of mineral ingredients such as calcium or iron
05/12/2005US20050100590 Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumours
05/12/2005US20050100589 Transdermal administration of ace inhibitors
05/12/2005US20050100567 Liquid concentrate for the preservation of cosmetic and pharmaceutical products
05/12/2005US20050100555 Synovial tissue binding peptide; amino acid sequence motifs; identify binding peptides by grafting tissue of first species into second having attenuated immunological response
05/12/2005US20050100545 Mutated antibody does not possess O-linked glycosylation, nucleic acids encoding prevents N-linked glycosylation; humanized and conjugated with radionucleotide to image target cells
05/12/2005US20050100543 Multivalent carriers of bi-specific antibodies
05/12/2005US20050100542 Cytotoxicity mediation of cells evidencing surface expression of CD44
05/12/2005US20050100530 Medicinal composition
05/12/2005US20050100528 Treat cancer; target cell surface associated antigen with monoclonal antibody; interlueukins, tumor necrosis factor, interferon
05/12/2005US20050098502 filtration of coal tar to remove impurities, then adding zinc pyrithione, surfactants and carriers to form mixtures used for the treatment of skin disorders
05/12/2005DE20023651U1 Aqueous solution formulations, useful for treating viral, tumorous and immune diseases, comprises interferon alpha, buffer system, stabilizing agent, nonionic surfactant, osmotic pressure regulator, and injection water
05/12/2005CA2545499A1 Antagonists of the bradykinin b1 receptor
05/12/2005CA2544307A1 Pharmaceutical compositions with synchronized solubilizer release
05/12/2005CA2544281A1 Tri-block copolymers and a process for the preparation of the same
05/12/2005CA2544049A1 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
05/12/2005CA2543945A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
05/12/2005CA2543919A1 Peptides whose uptake by cells is controllable
05/12/2005CA2543703A1 Psma formulations and uses thereof
05/12/2005CA2543530A1 Use of biocompatible polymers for the preparation of a composition or a medical device
05/12/2005CA2543443A1 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
05/12/2005CA2543242A1 Controlled release sterile injectable aripiprazole formulation and method
05/12/2005CA2543238A1 Compositions and dosage forms for enhanced absorption
05/12/2005CA2543227A1 Administration of levodopa and carbidopa
05/12/2005CA2543185A1 Compositions and dosage forms for ehnanced absorption of iron
05/12/2005CA2543181A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
05/12/2005CA2543177A1 Compositions and dosage forms for enhanced absorption of metformin
05/12/2005CA2543135A1 Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
05/12/2005CA2543084A1 Apparatus and method for enhancing transdermal drug delivery
05/12/2005CA2542968A1 Zeolite molecular sieves for the removal of toxins
05/12/2005CA2542875A1 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells
05/12/2005CA2542874A1 Compositions of stabilized dna for coating microprojections
05/12/2005CA2542777A1 Stabilised compositions
05/12/2005CA2542752A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
05/12/2005CA2541445A1 Nanoparticles for drug delivery
05/12/2005CA2535036A1 Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
05/12/2005CA2534236A1 Lipoparticles comprising proteins, methods of making, and using the same
05/12/2005CA2527495A1 High molecular weight polymers, devices and method for making and using same
05/11/2005EP1529536A1 Immunogenic composition having improved immunostimulation capacity
05/11/2005EP1528930A1 Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin
05/11/2005EP1528926A1 Novel pharmaceutical composition of ceftiofur
05/11/2005EP1528916A1 Multicomponent pharmaceutical dosage form
05/11/2005EP1528915A2 Liposomal vaccine
05/11/2005EP1528914A1 Antigenic compositions
05/11/2005EP1528913A1 Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating
05/11/2005EP1434571B1 Particle immobilized coatings and uses thereof
05/11/2005EP1399127B1 Olopatadine formulations for topical administration
05/11/2005EP1390399B1 Long lasting fusion peptide inhibitors for hiv infection
05/11/2005EP1330266B1 Method for making very fine particles consisting of a principle inserted in a host molecule
05/11/2005EP1315480B1 "slow release" pharmaceutical compositions comprising lithium carbonate
05/11/2005EP1165541B1 Dimeric compounds and as inhibitors of neuraminidase
05/11/2005EP1117382B1 Spray coated microparticles for use in needleless syringes
05/11/2005EP1100771B1 Compounds and compositions for delivering active agents
05/11/2005EP1083931B1 Stabilization of compositions containing ace inhibitors using magnesium oxide
05/11/2005EP1063992B1 Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations
05/11/2005EP0969815B1 Pharmaceutical compositions
05/11/2005EP0942716B1 Composition for transdermal delivery of drugs
05/11/2005CN1615339A Method for preparing gels
05/11/2005CN1615316A Novel immunogenic mimetics of multimer proteins
05/11/2005CN1615272A Calcium metasilicates and methods for making the same
05/11/2005CN1615156A Preparation of resinates
05/11/2005CN1615154A Oral administration of interferon-TAU
05/11/2005CN1615146A 生姜提取物制剂 Ginger extract preparation
05/11/2005CN1615139A 25-hydroxy vitamin D3 compositions
05/11/2005CN1615135A Oral dosage form of a sulfonamide prodrug such as parecoxib
05/11/2005CN1615131A Method for identification of tumor targeting enzymes
05/11/2005CN1615130A Taxane based compositions and methods of use
05/11/2005CN1615129A Process for affecting neurologic progression
05/11/2005CN1615124A Formulations
05/11/2005CN1615123A Bilayer pharmaceutical tablets comprising telmisartan and diuretic and their preparation
05/11/2005CN1615122A Pharmaceutical formulation comprising bicalutamide
05/11/2005CN1615120A Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
05/11/2005CN1615116A Water-in-oil emulsion composition and emulsion cosmetic therewith
05/11/2005CN1201005C Antigen binding fragments that specifically detect cancer cells, nucleotindes encoding the fragments, and use thereof for the prophylaxis and detection of cancers
05/11/2005CN1200951C Process for productio nof multiple cross-linked hyaluronic acid derivatives
05/11/2005CN1200950C Immuno-conjugated compound as protein or nucleic acid trasnferring carrier
05/11/2005CN1200949C Covalently bridged insulin dimers
05/11/2005CN1200736C Remidies for hepatitis
05/11/2005CN1200727C Pharmaceutical compositions based on alpha-cyclodextrin for oral administratio nof LH-RH analogues
05/11/2005CN1200711C Nicotine delivery system
05/11/2005CN1200706C Compositions and methods for treating or preventing inflammatory diseases
05/11/2005CN1200700C Pharmaceutical tramadol salts
05/11/2005CN1200697C Transnasal anticonvulsive compositions and modulated process
05/11/2005CN1200696C Patch containing anti-inflammatory agent
05/11/2005CN1200694C Solid medicaments obtained by extrusion of isomalt-containing polymer/active substance melt
05/11/2005CN1200693C Method for preparing coated drug particles and pharmaceutical formulations
05/11/2005CN1200691C Oral solution containing galanthamine and sweetening agent
05/11/2005CN1200690C Pressurised metered dose inhalers
05/11/2005CN1200684C Compositions comprising organosiloxane resins for delivering oral care substances
05/11/2005CN1200673C Antimicotic nail varnish composition
05/10/2005US6891037 Method for the isolation of polysaccharides
05/10/2005US6891028 Nucleic acids encoding transferrin receptor-like proteins
1 ... 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 ... 1712